What is the recommended vitamin D dosing for children with vitamin D deficiency?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Pediatric Vitamin D Deficiency Dosing

For children aged 1-18 years with vitamin D deficiency, treat with 2000 IU/day of vitamin D2 or D3 for at least 6 weeks, or alternatively 50,000 IU once weekly for 6 weeks, followed by maintenance therapy of 600-1000 IU/day. 1

Treatment Regimens by Age

Infants (0-1 year)

  • Treatment dose: 2000 IU/day of vitamin D2 or D3 for 6 weeks
  • Alternative: 50,000 IU once weekly for 6 weeks
  • Maintenance: 400-1000 IU/day after achieving 25(OH)D >30 ng/mL 1

Children (1-18 years)

  • Treatment dose: 2000 IU/day of vitamin D2 or D3 for at least 6 weeks
  • Alternative: 50,000 IU once weekly for at least 6 weeks
  • Maintenance: 600-1000 IU/day after achieving 25(OH)D >30 ng/mL 1

Recent research supports these recommendations, with a 2024 trial demonstrating that 4000 IU daily for 12 weeks effectively treats symptomatic deficiency in children aged 1-10 years 2, and a 2023 study showing 2000 IU daily is effective in infants 3.

Special Populations Requiring Higher Doses

Obese children and those on specific medications need 2-3 times the standard dose to achieve adequate vitamin D levels 1. This includes children taking:

  • Anticonvulsants
  • Glucocorticoids
  • Antifungals (ketoconazole)
  • AIDS medications

For these patients, treatment doses of 4000-6000 IU/day may be necessary, with maintenance of 1800-3000 IU/day 1.

Safety Considerations

The tolerable upper limits under medical supervision for correcting deficiency are 1:

  • 0-1 year: 2000 IU/day
  • 1-18 years: 4000 IU/day

Both daily and intermittent (weekly/monthly) dosing regimens are effective. Recent trials show transient asymptomatic hypercalcemia can occur in 5-15% of treated children but resolves spontaneously 2, 3. Monitor serum calcium and 25(OH)D levels during treatment, particularly at 4 and 12 weeks.

Choice of Vitamin D Formulation

Either vitamin D2 (ergocalciferol) or vitamin D3 (cholecalciferol) can be used for treatment and prevention 1. Both formulations are equally effective at maintaining serum 25(OH)D levels, though some evidence suggests D3 may produce slightly higher levels in certain populations 1.

Treatment Goals

The target is to achieve serum 25(OH)D levels above 30 ng/mL (75 nmol/L) 1. This typically requires 6 weeks of treatment at the doses specified above. After reaching this target, transition to maintenance dosing to prevent recurrence.

Common Pitfalls to Avoid

  • Don't use single massive bolus doses (>150,000 IU) in infants under 12 months - this increases hypercalcemia risk 4
  • Don't forget calcium supplementation - children with symptomatic deficiency often need concurrent calcium (50 mg/kg/day in infants, 500 mg/day in older children) 2, 3
  • Don't assume compliance - if adherence is questionable, weekly dosing (50,000 IU) may be more practical than daily dosing 1
  • Don't stop monitoring - check 25(OH)D levels after treatment completion to confirm adequacy before transitioning to maintenance 1

References

Related Questions

What are the clinical manifestations of vitamin D deficiency and toxicity?
What is the appropriate treatment for vitamin D deficiency in a 3½-year-old child?
What daily prophylactic dose of vitamin D3 (cholecalciferol) should be given to otherwise healthy infants, children, and adolescents to prevent vitamin D deficiency?
What is the appropriate treatment for low vitamin D in a 37‑year‑old female?
What is the appropriate vitamin D3 dosage for a 9-year-old child with vitamin D deficiency?
I received a letter from Express CRPIT titled "Patient Safety and Health Consideration"; what does this mean?
What fasting serum C‑terminal telopeptide (CTX) value indicates adequate bone resorption suppression in a postmenopausal woman taking alendronate?
What do black longitudinal melanonychia (black lines) on the fingernails indicate?
Can a patient experiencing opioid withdrawal be given lorazepam (Ativan)?
Should a thyroid‑stimulating hormone level of 5.13 mIU/L be treated with levothyroxine?
In a patient with a negative Bravo pH study for gastroesophageal reflux disease who is taking gabapentin and experiencing increased viscous saliva secretions and cough, what foods or nutraceuticals could help alleviate these symptoms?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.